

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 12/14/2022
Time Report Requested: 13:17:38
Lab: Burleson Research Technologies

Study Number: I20045
Study Gender: Female
PWG Approval Date: See web page for date of PWG Approval
Version: v1.4.3
Stat Version: v2.9.1A

Females: SRBC Cohort											
Phase Day	Treatment Groups (mg/kg)										
	0		12.5			25			50		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	21.1 ± 0.5	8	21.2 ± 0.3	100.8	8	21.5 ± 0.5	102.3	8	20.8 ± 0.4	98.7	8
SD6	20.9 ± 0.5	8	21.2 ± 0.4	101.5	7	21.5 ± 0.6	102.7	8	21.2 ± 0.6	101.6	8
SD13	21.3 ± 0.7	8	22.2 ± 0.3	104.2	6	21.5 ± 1.0	101.1	5	21.6 ± 0.7	101.2	8
SD20	22.1 ± 0.7	8	23.2 ± 0.4	104.9	6	22.4 ± 1.0	101.3	5	23.0 ± 0.9	104.1	8
SD27	22.8 ± 0.7	8	23.8 ± 0.4	104.5	6	23.1 ± 1.1	101.4	5	23.4 ± 0.9	102.7	8
SD28	22.6 ± 0.7	8	23.9 ± 0.4	105.7	6	22.9 ± 1.0	101.5	5	23.2 ± 1.0	102.7	8

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 12/14/2022
Time Report Requested: 13:17:38
Lab: Burleson Research Technologies

Females: SRBC Cohort

Phase Day	Treatment Groups (mg/kg)											
	100			200			400			800		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	21.3 ± 0.5	100.9	8	21.6 ± 0.4	102.4	8	21.5 ± 0.3	102.1	8	21.1 ± 0.4	100.0	8
SD6	21.4 ± 0.4	102.3	8	21.3 ± 0.4	101.9	8	21.8 ± 0.3	104.5	8	NA		
SD13	22.2 ± 0.4	104.2	6	21.5 ± 0.6	100.9	6	22.1 ± 0.4	103.5	7	NA		
SD20	23.6 ± 0.6	107.0	5	22.8 ± 0.7	103.1	6	23.1 ± 0.2	104.8	7	NA		
SD27	24.2 ± 0.8	106.1	5	22.9 ± 0.7	100.4	6	23.5 ± 0.3	103.1	7	NA		
SD28	24.3 ± 0.9	107.8	5	23.0 ± 0.7	101.6	6	23.2 ± 0.3	102.5	7	NA		

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 12/14/2022
Time Report Requested: 13:17:38
Lab: Burleson Research Technologies

Females: SRBC Cohort

Phase Day	Treatment Groups (mg/kg)		
	50 mg/kg CPS		
	Wt (g)	% of CNTL	N
SD0	20.6 ± 0.3	97.6	8
SD6	21.6 ± 0.6	103.5	8
SD13	22.2 ± 0.7	104.3	8
SD20	23.3 ± 0.9	105.5	8
SD27	23.1 ± 1.0	101.5	8
SD28	22.4 ± 1.0	99.2	8

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 12/14/2022
Time Report Requested: 13:17:38
Lab: Burleson Research Technologies

Females: Immunopath Cohort

Phase Day	Treatment Groups (mg/kg)										
	0		12.5			25			50		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	21.8 ± 0.5	8	21.6 ± 0.4	99.1	8	21.8 ± 0.2	99.9	8	21.8 ± 0.4	99.9	8
SD6	21.9 ± 0.6	8	21.2 ± 0.3	96.9	8	22.1 ± 0.3	100.8	7	22.5 ± 0.5	102.6	6
SD13	22.5 ± 0.7	8	21.6 ± 0.3	96.1	8	22.3 ± 0.2	99.1	6	22.7 ± 0.5	100.7	5
SD20	23.6 ± 0.8	8	22.5 ± 0.5	95.2	8	23.2 ± 0.3	98.5	6	23.1 ± 0.6	98.1	5
SD28	23.7 ± 1.0	7	22.6 ± 0.7	95.7	7	23.5 ± 0.6	99.3	6	23.7 ± 0.8	100.3	5

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 12/14/2022
Time Report Requested: 13:17:38
Lab: Burleson Research Technologies

Females: Immunopath Cohort												
Treatment Groups (mg/kg)												
Phase Day	100			200			400			800		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	21.5 ± 0.4	98.7	8	21.9 ± 0.5	100.1	8	21.0 ± 0.4	96.2	8	21.9 ± 0.2	100.3	8
SD6	21.1 ± 0.4	96.2	6	22.0 ± 0.4	100.3	7	21.8 ± 0.6	99.5	8	NA		
SD13	21.9 ± 0.8	97.3	5	22.4 ± 0.5	99.4	7	22.4 ± 0.8	99.4	8	NA		
SD20	22.7 ± 0.9	96.1	5	23.2 ± 0.6	98.4	7	23.3 ± 0.8	98.8	8	NA		
SD28	22.9 ± 0.9	96.7	5	23.1 ± 0.7	97.6	6	22.8 ± 0.7	96.3	8	NA		

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 12/14/2022
Time Report Requested: 13:17:38
Lab: Burleson Research Technologies

Females: Immunopath Cohort

Phase Day	Treatment Groups (mg/kg)		
	50 mg/kg CPS		
	Wt (g)	% of CNTL	N
SD0	22.7 ± 0.2	104.1	8
SD6	23.0 ± 0.4	105.1	8
SD13	23.9 ± 0.6	106.1	8
SD20	24.9 ± 0.4	105.5	8
SD28	23.7 ± 0.6	100.2	8

Study Number: I20045

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary

Test Compound: Phenanthrene

CAS Number: 85-01-8

Date Report Requested: 12/14/2022

Time Report Requested: 13:17:38

Lab: Burleson Research Technologies

LEGEND

Data are displayed as mean $\pm$ SEM

SD – Study Day

Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

NA - Not Available

**** END OF REPORT ****